Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $152.00 Average PT from Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has earned an average rating of “Moderate Buy” from the twenty-five analysts that are presently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation, eighteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $152.00.

A number of brokerages have recently issued reports on NBIX. UBS Group boosted their price target on shares of Neurocrine Biosciences from $174.00 to $193.00 and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, May 1st. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 21st. JPMorgan Chase & Co. increased their price objective on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Finally, Citigroup boosted their target price on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd.

Insider Buying and Selling at Neurocrine Biosciences

In related news, Director Shalini Sharp sold 1,106 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $141.90, for a total transaction of $156,941.40. Following the transaction, the director now owns 994 shares of the company’s stock, valued at $141,048.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Neurocrine Biosciences news, Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the completion of the sale, the director now owns 26,504 shares in the company, valued at approximately $3,537,223.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Shalini Sharp sold 1,106 shares of the company’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $141.90, for a total transaction of $156,941.40. Following the transaction, the director now directly owns 994 shares of the company’s stock, valued at approximately $141,048.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 88,697 shares of company stock worth $11,975,615. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently bought and sold shares of the stock. Mather Group LLC. acquired a new stake in Neurocrine Biosciences during the first quarter worth about $26,000. RFP Financial Group LLC grew its holdings in shares of Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after purchasing an additional 149 shares during the period. Headinvest LLC acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $28,000. Lindbrook Capital LLC raised its holdings in Neurocrine Biosciences by 85.0% in the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after buying an additional 96 shares during the period. Finally, EdgeRock Capital LLC acquired a new position in Neurocrine Biosciences during the fourth quarter valued at approximately $31,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Trading Up 1.8 %

Shares of NBIX stock opened at $140.11 on Friday. The company has a market capitalization of $14.10 billion, a P/E ratio of 38.60 and a beta of 0.37. The business’s 50 day moving average is $137.47 and its two-hundred day moving average is $135.94. Neurocrine Biosciences has a twelve month low of $93.28 and a twelve month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The firm had revenue of $515.30 million during the quarter, compared to analysts’ expectations of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. As a group, equities analysts predict that Neurocrine Biosciences will post 4.19 earnings per share for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.